Online Order Form
- Package Insert – TheraSphere® Yttrium-90 Glass Microspheres – Rev. 14. Biocompatibles UK Ltd, a BTG International group company.
- Walrand S, Hesse M, Jamar F, et al. A hepatic dose-toxicity model opening the way toward individualized radioembolization planning. J Nucl Med 2014;55(8):1317–22.
- Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52(5):1741–9.
- Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy off radioembolization. Int J Radiat Oncol Biol Phys 2011;79(1):163–71.
- Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57(5):1826–37.
- Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014;60(1):192–201.
- Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140(2):497–507.
- Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9(8):1920–8.
- Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007;68(1):13–23.
- Merkel C, Montagnese S, Amodio P. Functional Anatomy of Liver Circulation. Functional Molecular Imaging in Hepatology. Ed. Keiding S, Sorensen M, Bentham Science, 2014.
- Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006;17:1251–78.
- Kulik M, Carr B, Mulcahy M, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47(1):71–81.
- Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138(1):52–64.
- Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100(10):698–711.
- Reference Manual – TheraSphere® Yttrium-90 Glass Microspheres – Biocompatibles UK Ltd, a BTG International group company.
- BTG, Data on file. June 2, 2015.
- Salem R, Gilbertsen M, Butt Z, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013;11(10):1358–65.
- Steel J, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). Psycho-Oncology 2004;13(2):73–9.
- Lambert B, Sturm E, Mertens J, et al. Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nuc Mol Imaging 2011;38(1):2117–2124.
- McCann J, Larkin A, Martino L, et al. Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary? J Vasc Interv Radiol 2012;23(1):661–7.
- GLOBOCAN website. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed June 29, 2015.
- American Cancer Society. Liver cancer. Available at www.cancer.org. Accessed June 29, 2015.
- Chowdhury R, Satoskar R. Chapter 2: Surveillance for Hepatocellular Carcinoma. Primary Liver Cancer Surveillance, Diagnosis and Treatment. Humana Press; 2012
- Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47(1):71–81.
- Abdel-Misih SRZ, Bloomston M. Liver Anatomy. Surgical Clinics 2010;90(4):643–53.
- Dancygier H. Clinical Hepatology. Springer-Verlag Berlin Heidelberg; 2010.
- Canadian Liver Foundation. Cirrhosis of the liver. Available at www.liver.ca. Accessed June 29, 2015.
- Eipel C, Abshagen K, Vollmar B. Regulation of hepatic blood flow: The hepatic arterial buffer response revisited. World J Gastroenterol 2010;16(48):6046–57.
- Barrett K, Brooks H, Boitano S, et al. Ganong’s Review of Medical Physiology, 23rd edition. McGraw-Hill; 2012.
- Canadian Cancer Society, Liver cancer. Available at www.cancer.ca. Accessed June 29, 2015.
- Cancer Research UK. The liver. Available at www.cancerresearchuk.org. Accessed June 29, 2015.
- National Library of Medicine. How does the liver work. Available at www.ncbi.nlm.nih.gov/pubmedhealth/PMH0072577. Accessed June 29, 2015.
- Cancer Research UK. Risks and causes of liver cancer. Available at www.cancerresearchuk.org. Accessed June 29, 2015.
- American Cancer Society. What are the risk factors for liver cancer? Available at www.cancer.org. Accessed June 29, 2015.
- Wei SJ. All about liver cancer. Available at www.oncolink.org. Accessed June 29, 2015.
- Cancer Research UK. Symptoms of liver cancer. Available at www.cancerresearchuk.org. Accessed June 29, 2015.
- American Society of Clinical Oncology. Liver cancer: symptoms and signs. Available at www.cancer.net. Accessed June 29, 2015.
- American Society of Clinical Oncology. Liver cancer: diagnosis. Available at www.cancer.net. Accessed June 29, 2015.
- Garin E, Rolland Y, Pracht M, et al. High impact of macroaggegated albumin-based tumour does on response and overall survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microsphere radioembolization. Liver Int 2017;37(1):101–10.
- Garin E, Lenoir L, Rolland Y, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med 2012;53(2):255–63.
- Laffont S, Rolland Y, Ardisson V, et al. Occupational radiation exposure for medical staff performing 90Y-loaded microsphere radioembolization. Eur J Nucl Med Mol Imaging 2016;43(5):824–31.
- Garin E, Laffont S, Rolland Y, et al. Safe radiation exposure of medical personnel using simple radioprotection means while administering 131I-lipiodol therapy for hepatocellular carcinoma. Nucl Med Comm 2003;24:671–8.
- Mauxion T, Fischer A, Dreher M, et al. Dosimetric analysis of 90Y glass and resin microsphere distributions in hepatic tumors: From the microsphere coverage to the absorbed dose. J Vasc Interv Radiol 2016;27:S61.
- NCCN Guidelines: Hepatobiliary Cancers Version 2.2016.
- Atassi B, Bangash AK, Bahrani A, et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 2008;28(1):81–99.